Synopsis
Synopsis
0
JDMF
0
VMF
0
Canada
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dexchlorpheniramine
2. Dexchlorpheniramine Maleate (1:1), (+-)-isomer
3. Dexchlorpheniramine Maleate (1:1), (r)-isomer
4. Dexchlorpheniramine Maleate (1:1), (s)-isomer
5. Dexchlorpheniramine Monohydrochloride
6. Dexchlorpheniramine Sodium Maleate (1:1)
7. Dexchlorpheniramine, (+-)-isomer
8. Dexchlorpheniramine, (r)-isomer
9. Dexchlorpheniramine, Monohydrochloride, (s)-isomer
10. Dexclor
11. Dexclorfeniramine
12. Dextrochlorpheniramine Maleate
13. Polaramin
14. Polaramine
15. Polargen Td
16. Polaronil
1. 2438-32-6
2. Polaramine
3. (+)-chlorpheniramine Maleate
4. D-chlorpheniramine Maleate
5. Dexchloropheniramine Maleate
6. Mylaramine
7. Dexchlorpheniramine (maleate)
8. Chlorpheniramine D-form Maleate
9. S-(+)-chlorpheniramine Maleate Salt
10. Dexchlorpheniramine Maleate, Usp
11. Chebi:4465
12. B10yd955qw
13. Chlorpheniramine Maleate, (s)-
14. Dexchlorpheniramine Maleate [usp]
15. (z)-but-2-enedioic Acid;(3s)-3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine
16. Nsc-759156
17. Dextrochlorpheniramine Maleate
18. Dexchlorpheniramine Maleate (usp)
19. (s)-3-(4-chlorophenyl)-n,n-dimethyl-3-(pyridin-2-yl)propan-1-amine Maleate
20. (gamma-(4-chlorophenyl)-pyridine-2-propyl)(dimethyl)ammonium Hydrogen (z)-maleate
21. Sr-01000075763
22. Unii-b10yd955qw
23. Polar Amine
24. S-(+)-chlorpheniramine Maleate
25. Rescon Jr
26. Rescon Mx
27. Mylaramine (tn)
28. Polaramine (tn)
29. (s)-chlorpheniramine Maleate Salt
30. Einecs 219-450-6
31. Mfcd00079046
32. Dexchlorpheniraminmaleat
33. Mls001401384
34. Schembl119500
35. Chembl1200927
36. Dtxsid001017216
37. Hms2052e15
38. Hms2233i15
39. Hms3260f10
40. D-chlorpheniramine Maleate (jp17)
41. Hy-b1062
42. Tox21_500264
43. Bdbm50247890
44. (+)-2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine Maleate (1:1)
45. Akos015962825
46. Ccg-101121
47. Cs-4618
48. Db09555
49. Lp00264
50. Nc00371
51. Nsc 759156
52. (2z)-but-2-enedioic Acid; [(3s)-3-(4-chlorophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
53. D-chlorpheniramine Maleate [jan]
54. Ncgc00093722-01
55. Ncgc00093722-02
56. Ncgc00093722-03
57. Ncgc00260949-01
58. 2-pyridinepropanamine, .gamma.-(4-chlorophenyl)-n,n-dimethyl-, (s)-, (z)-2-butenedioate (1:1)
59. Ac-19009
60. As-17464
61. Smr000471617
62. Dexchlorpheniramine Maleate [vandf]
63. Dexchlorpheniramine Maleate [usp-rs]
64. Dexchlorpheniramine Maleate [who-dd]
65. Chlorpheniramine D-form Maleate [mi]
66. Eu-0100264
67. C 4915
68. C07783
69. D00668
70. Dexchlorpheniramine Maleate [ep Impurity]
71. Dexchlorpheniramine Maleate [orange Book]
72. 438d326
73. A924268
74. Dexchlorpheniramine Maleate [ep Monograph]
75. Dexchlorpheniramine Maleate [usp Monograph]
76. Sr-01000075763-1
77. Sr-01000075763-4
78. Q27106393
79. (gammas)-gamma-(4-chlorophenyl)-n,n-dimethyl-2-pyridinepropanamine Maleate
80. Dexchlorpheniramine Maleate, European Pharmacopoeia (ep) Reference Standard
81. Gammas-(4-chlorophenyl)-n,n-dimethyl-2-pyridinepropanamine, 2z-butenedioate
82. (+)-2-(p-chloro-.alpha.-(2-(dimethylamino)ethyl)benzyl)pyridine Maleate (1:1)
83. Dexchlorpheniramine Maleate, United States Pharmacopeia (usp) Reference Standard
84. Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)-, Maleate (1:1), (+)-
85. 2-pyridinepropanamine, Gamma-(4-chlorophenyl)-n,n-dimethyl-, (s)-, (z)-2-butenedioate (1:1)
Molecular Weight | 390.9 g/mol |
---|---|
Molecular Formula | C20H23ClN2O4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 390.1346349 g/mol |
Monoisotopic Mass | 390.1346349 g/mol |
Topological Polar Surface Area | 90.7 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 368 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Dexchlorpheniramine maleate |
PubMed Health | Dexchlorpheniramine Maleate (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Each 5 mL (teaspoonful) contains:Dexchlorpheniramine Maleate, USP2 mgAlcohol not more than7.0%Dexchlorpheniramine Maleate, USP, an antihistamine agent, is a white, odorless crystalline powder that is freely soluble in water. The molecular formula is... |
Active Ingredient | Dexchlorpheniramine maleate |
Dosage Form | Syrup |
Route | Oral |
Strength | 2mg/5ml |
Market Status | Prescription |
Company | Wockhardt |
2 of 2 | |
---|---|
Drug Name | Dexchlorpheniramine maleate |
PubMed Health | Dexchlorpheniramine Maleate (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Each 5 mL (teaspoonful) contains:Dexchlorpheniramine Maleate, USP2 mgAlcohol not more than7.0%Dexchlorpheniramine Maleate, USP, an antihistamine agent, is a white, odorless crystalline powder that is freely soluble in water. The molecular formula is... |
Active Ingredient | Dexchlorpheniramine maleate |
Dosage Form | Syrup |
Route | Oral |
Strength | 2mg/5ml |
Market Status | Prescription |
Company | Wockhardt |
Dexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis, vasomotor rhiniti, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, and dermographism.
In allergic reactions, an allergen binds to IgE antibodies on mast cells and basophils. Once this occurs IgE receptors crosslink with each other triggering a series of events that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexchlorpheniramine, is a histamine H1 antagonist of the alkylamine class. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Absorption
Oral bioavailability in rats 40.5%
Route of Elimination
Renal excretion
Volume of Distribution
321L
Clearance
9.8L/h
Hepatic metabolism. Major metabolism by CYP 2D6 and minor metabolism by 3A4, 2C11 and 2B1.
20-30 h
Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Dexchlorpheniramine is the predominant active isomer of chlorpheniramine and is approximately twice as active as the racemic compound.
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
86
PharmaCompass offers a list of Dexchloropheniramine Maleate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dexchloropheniramine Maleate manufacturer or Dexchloropheniramine Maleate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dexchloropheniramine Maleate manufacturer or Dexchloropheniramine Maleate supplier.
PharmaCompass also assists you with knowing the Dexchloropheniramine Maleate API Price utilized in the formulation of products. Dexchloropheniramine Maleate API Price is not always fixed or binding as the Dexchloropheniramine Maleate Price is obtained through a variety of data sources. The Dexchloropheniramine Maleate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dexchlorpheniramine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dexchlorpheniramine, including repackagers and relabelers. The FDA regulates Dexchlorpheniramine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dexchlorpheniramine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dexchlorpheniramine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dexchlorpheniramine supplier is an individual or a company that provides Dexchlorpheniramine active pharmaceutical ingredient (API) or Dexchlorpheniramine finished formulations upon request. The Dexchlorpheniramine suppliers may include Dexchlorpheniramine API manufacturers, exporters, distributors and traders.
click here to find a list of Dexchlorpheniramine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dexchlorpheniramine DMF (Drug Master File) is a document detailing the whole manufacturing process of Dexchlorpheniramine active pharmaceutical ingredient (API) in detail. Different forms of Dexchlorpheniramine DMFs exist exist since differing nations have different regulations, such as Dexchlorpheniramine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dexchlorpheniramine DMF submitted to regulatory agencies in the US is known as a USDMF. Dexchlorpheniramine USDMF includes data on Dexchlorpheniramine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dexchlorpheniramine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dexchlorpheniramine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dexchlorpheniramine Drug Master File in Korea (Dexchlorpheniramine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dexchlorpheniramine. The MFDS reviews the Dexchlorpheniramine KDMF as part of the drug registration process and uses the information provided in the Dexchlorpheniramine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dexchlorpheniramine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dexchlorpheniramine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dexchlorpheniramine suppliers with KDMF on PharmaCompass.
A Dexchlorpheniramine CEP of the European Pharmacopoeia monograph is often referred to as a Dexchlorpheniramine Certificate of Suitability (COS). The purpose of a Dexchlorpheniramine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dexchlorpheniramine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dexchlorpheniramine to their clients by showing that a Dexchlorpheniramine CEP has been issued for it. The manufacturer submits a Dexchlorpheniramine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dexchlorpheniramine CEP holder for the record. Additionally, the data presented in the Dexchlorpheniramine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dexchlorpheniramine DMF.
A Dexchlorpheniramine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dexchlorpheniramine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dexchlorpheniramine suppliers with CEP (COS) on PharmaCompass.
A Dexchlorpheniramine written confirmation (Dexchlorpheniramine WC) is an official document issued by a regulatory agency to a Dexchlorpheniramine manufacturer, verifying that the manufacturing facility of a Dexchlorpheniramine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dexchlorpheniramine APIs or Dexchlorpheniramine finished pharmaceutical products to another nation, regulatory agencies frequently require a Dexchlorpheniramine WC (written confirmation) as part of the regulatory process.
click here to find a list of Dexchlorpheniramine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dexchlorpheniramine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dexchlorpheniramine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dexchlorpheniramine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dexchlorpheniramine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dexchlorpheniramine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dexchlorpheniramine suppliers with NDC on PharmaCompass.
Dexchlorpheniramine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dexchlorpheniramine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dexchlorpheniramine GMP manufacturer or Dexchlorpheniramine GMP API supplier for your needs.
A Dexchlorpheniramine CoA (Certificate of Analysis) is a formal document that attests to Dexchlorpheniramine's compliance with Dexchlorpheniramine specifications and serves as a tool for batch-level quality control.
Dexchlorpheniramine CoA mostly includes findings from lab analyses of a specific batch. For each Dexchlorpheniramine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dexchlorpheniramine may be tested according to a variety of international standards, such as European Pharmacopoeia (Dexchlorpheniramine EP), Dexchlorpheniramine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dexchlorpheniramine USP).